This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
HealthdirectFree Australian health advice you can count on. — Description, Dosage, Side Effects | PillsCard
OTC
HealthdirectFree Australian health advice you can count on.
3.5MG/VIAL, Injectable
INN: BORTEZOMIB
Data updated: 2026-04-25
Available in:
🇬🇧🇫🇷🇵🇹
Form
INJECTABLE
Dosage
3.5MG/VIAL
Route
INTRAVENOUS, SUBCUTANEOUS
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
TAKEDA PHARMACEUTICALS USA INC
ATC Code
L01XG01
Source
FDA_OB · 021602
(
ARTG
)
- VELCADE, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.
- VELCADE, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.
- VELCADE is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
- VELCADE in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
⚠️ Warnings
• Caution should be exercised in patients with history of heart disease, infection, sugar, fainting, high cholesterol, high or low blood pressure, weakness, alcoholism, kidney or liver disease, any allergy, who are taking other medications, during pregnancy and breastfeeding.
• It may cause dizziness, drowsiness, lightheadedness or blurred vision, do not drive a car or operate machinery and get up slowly from bed while taking this medication.
